Point72 Asset Management, L.P. - SYNDAX PHARMACEUTICALS INC ownership

SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 117 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.53 and the average weighting 0.2%.

Quarter-by-quarter ownership
Point72 Asset Management, L.P. ownership history of SYNDAX PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$30,407,799
+17.7%
2,094,201
+69.6%
0.09%
+15.6%
Q2 2023$25,844,364
+133.4%
1,234,800
+135.5%
0.08%
+126.5%
Q1 2023$11,075,328
-52.9%
524,400
-43.2%
0.03%
-57.5%
Q4 2022$23,500,530
+275.6%
923,400
+156.5%
0.08%
+220.0%
Q1 2022$6,257,000
-19.0%
360,000
+2.0%
0.02%
-19.4%
Q4 2021$7,729,000
-12.3%
353,100
-23.4%
0.03%
-20.5%
Q3 2021$8,808,000
+64.2%
460,900
+47.5%
0.04%
+62.5%
Q2 2021$5,364,000
-74.7%
312,400
-67.0%
0.02%
-75.8%
Q1 2021$21,170,000
-16.8%
946,800
-17.2%
0.10%
-20.2%
Q4 2020$25,440,000
+937.9%
1,143,900
+588.9%
0.12%
+853.8%
Q3 2020$2,451,000
+78.4%
166,037
-2.3%
0.01%
+116.7%
Q3 2018$1,374,000
-67.8%
170,000
-43.3%
0.01%
-66.7%
Q1 2018$4,269,000
+214.4%
300,000
+203.0%
0.02%
+125.0%
Q1 2017$1,358,00099,0000.01%
Other shareholders
SYNDAX PHARMACEUTICALS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Kynam Capital Management, LP 1,932,800$33,592,00010.90%
Aisling Capital Management LP 1,025,000$17,815,0009.61%
Frazier Life Sciences Management, L.P. 3,195,403$55,536,0004.73%
Paradigm Biocapital Advisors LP 701,356$12,190,0003.22%
SPHERA FUNDS MANAGEMENT LTD. 1,277,413$22,201,0003.14%
Nantahala Capital Management 2,692,303$46,792,0002.07%
Avidity Partners Management LP 4,823,400$83,831,0001.75%
DAFNA Capital Management LLC 371,987$6,465,0001.68%
ACUTA CAPITAL PARTNERS, LLC 206,126$3,582,0001.67%
BVF INC/IL 2,394,714$41,620,0001.66%
View complete list of SYNDAX PHARMACEUTICALS INC shareholders